Appendix

Workshop Program

Collaboration Between Government and Industry: Challenges and Opportunities for HIV Drug and Vaccine Development

May 6, 1994

9:00

Welcome and Introduction

  • Paul Volberding, Chief, AIDS Program and Clinical Oncology, San Francisco General Hospital, and Roundtable Cochair

9:15

Importance and Value of Government-Industry Collaboration on HIV Drug and Vaccine Development

  • Patrick Gage, Chief Operating Officer, Genetics Institute, Inc.

9:30

Historical Perspectives on Government Technology Transfer Policy and the Pharmaceutical Industry

Discussion Leader: Peter Barton Hutt, Partner, Covington & Burling

Understanding the Legislative History of Intellectual Property Rights Involving the Pharmaceutical Industry

  • Peter Barton Hutt, Partner, Covington & Burling

Understanding the History of Fair Pricing Clauses and Their Implementation in Government Licensing of Intellectual Property

  • Thomas Mays, Director, Office of Technology Development, National Cancer Institute

10:00

Discussion

10:30

Break



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 18
Government and Industry Collaboration in AIDS Drug Development: Summary of a Workshop Held on May 6, 1994 Appendix Workshop Program Collaboration Between Government and Industry: Challenges and Opportunities for HIV Drug and Vaccine Development May 6, 1994 9:00 Welcome and Introduction Paul Volberding, Chief, AIDS Program and Clinical Oncology, San Francisco General Hospital, and Roundtable Cochair 9:15 Importance and Value of Government-Industry Collaboration on HIV Drug and Vaccine Development Patrick Gage, Chief Operating Officer, Genetics Institute, Inc. 9:30 Historical Perspectives on Government Technology Transfer Policy and the Pharmaceutical Industry Discussion Leader: Peter Barton Hutt, Partner, Covington & Burling Understanding the Legislative History of Intellectual Property Rights Involving the Pharmaceutical Industry Peter Barton Hutt, Partner, Covington & Burling Understanding the History of Fair Pricing Clauses and Their Implementation in Government Licensing of Intellectual Property Thomas Mays, Director, Office of Technology Development, National Cancer Institute 10:00 Discussion 10:30 Break

OCR for page 18
Government and Industry Collaboration in AIDS Drug Development: Summary of a Workshop Held on May 6, 1994 10:45 Impediments to Collaboration on HIV Drug and Vaccine Development: Defining the Issues Discussion Leader: Patrick Gage, Chief Operating Officer, Genetics Institute, Inc. Commentary from a Government/NIH Perspective Bruce Chabner, Director, Division of Cancer Treatment, National Cancer Institute A View from the Pharmaceutical Industry Stephen Carter, Senior Vice President, World Wide Clinical Research & Development, Bristol-Myers Squibb Pharmaceutical Research Institute Practical Implications of Rules Governing Intellectual Property Developed from Collaborative Relationships Harold Edgar, Professor of Law, Columbia University School of Law 11:30 Discussion 1:00 Lunch 2:00 Overcoming Obstacles to Collaboration and Promoting HIV Drug and Vaccine Development: Proposals for Resolution Discussion Leader: Martin Delaney, Founding Director, Project Inform Industry Perspective David Barry, Group Director, Research, Development and Medical Affairs, The Wellcome Research Laboratories Government/NIH Perspective Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases Congressional/Legislative Response Timothy Westmoreland, Counsel, Subcommittee on Health and the Environment, U.S. House of Representatives

OCR for page 18
Government and Industry Collaboration in AIDS Drug Development: Summary of a Workshop Held on May 6, 1994   David Schulke, Chief Health Policy Advisor, The Honorable Ron Wyden, U.S. House of Representatives, Member, Energy and Commerce Committee, Health and Environment Subcommittee 2:40 Discussion 4:15 Consideration of Future Directions: Summary of Salient Issues Daniel Hoth, Senior Vice President and Chief Medical Officer, Cell Genesys 4:45 Closing Remarks Barton Haynes, F.M. Hanes Professor of Medicine; Director, Duke University Arthritis Center; and Roundtable Cochair 5:00 Adjourn